Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia flag Australia · Delayed Price · Currency is AUD
2.890
+0.100 (3.58%)
At close: Feb 5, 2026

Clarity Pharmaceuticals Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Other Revenue
9.4611.519.86.463.2
9.4611.519.86.463.2
Revenue Growth (YoY)
-17.76%17.41%51.74%102.07%14.62%
Gross Profit
9.4611.519.86.463.2
Selling, General & Admin
11.689.944.714.613.83
Research & Development
66.8845.7831.4618.99.68
Operating Expenses
78.5655.7236.1623.5113.51
Operating Income
-69.09-44.21-26.36-17.05-10.31
Interest & Investment Income
4.762.771.860.10.04
Currency Exchange Gain (Loss)
0.45-0.59---
EBT Excluding Unusual Items
-63.88-42.03-24.5-16.95-10.27
Other Unusual Items
----6.780.05
Pretax Income
-63.88-42.03-24.5-23.74-10.22
Income Tax Expense
0.420.30.10.02-
Net Income
-64.3-42.32-24.6-23.75-10.22
Net Income to Common
-64.3-42.32-24.6-23.75-10.22
Shares Outstanding (Basic)
319273260248176
Shares Outstanding (Diluted)
319273260248176
Shares Change (YoY)
16.86%5.22%4.81%40.37%20.54%
EPS (Basic)
-0.20-0.15-0.09-0.10-0.06
EPS (Diluted)
-0.20-0.15-0.10-0.10-0.06
Free Cash Flow
-54.95-43.74-27.55-13.53-7.74
Free Cash Flow Per Share
-0.17-0.16-0.11-0.06-0.04
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-730.16%-384.24%-269.00%-263.94%-322.65%
Profit Margin
-679.45%-367.82%-251.03%-367.78%-319.77%
Free Cash Flow Margin
-580.71%-380.14%-281.07%-209.43%-242.06%
EBITDA
-68.91-44.06-26.26-17-10.3
EBITDA Margin
---267.97%-263.22%-
D&A For EBITDA
0.190.150.10.050.02
EBIT
-69.09-44.21-26.36-17.05-10.31
EBIT Margin
---269.00%-263.94%-
Revenue as Reported
14.6814.2811.666.553.29
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.